Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial

Pierluigi Tricoci, Yuliya Lokhnygina, Zhen Huang, F Van De Werf, Jan Cornel, Edmond Chen, Lars Wallentin, Claes Held, Philip Aylward, David Moliterno, Lisa Jennings, Harvey White, Paul Armstrong, Robert Harrington, John Strony, Kenneth Mahaffey

    Research output: Contribution to journalArticle

    16 Citations (Scopus)

    Abstract

    Background: Protease-activated receptor 1 antagonism with vorapaxar represents a novel strategy for platelet inhibition. In TRACER, vorapaxar was compared with placebo plus standard of care among 12,944 patients with non-ST-segment elevation acute coronary syndromes. We anticipated that most patients would have received clopidogrel as part of standard care. We investigated the modification of vorapaxar's effect associated with clopidogrel use over time. Methods: The marginal structural model method was used to estimate causal modification of vorapaxar effect by use of clopidogrel over time. The primary outcomes were the composite of cardiovascular death, myocardial infarction, or stroke and Global Use of Strategies to Open Occluded Coronary Arteries moderate or severe bleeding. The event accrual period excluded the time during which clopidogrel was clinically warranted. Results: Among 12,887 patients who received study medication, 11,117 (86.3%) received clopidogrel before randomization, of whom 38.5% stopped later in the trial (median time to stoppage 200 days with placebo; interquartile range [IQR] 14-367) (186 days with vorapaxar; IQR 17-366). In total, 1,770 (13.7%) patients were not on clopidogrel at randomization, of whom 47.8% started afterward (median time to start 2 days; IQR 2-4). During the period of event accrual, vorapaxar was associated with a 26% reduction in the composite of cardiovascular death, myocardial infarction, or stroke when used with clopidogrel (hazard ratio [HR] 0.74; 95% CI 0.60-0.91) and a 24% reduction when used without clopidogrel (HR 0.76; 95% CI 0.56-1.02) (interaction; P = .89). The hazard of Global Use of Strategies to Open Occluded Coronary Arteries bleeding with vorapaxar was not significantly different without clopidogrel (HR 1.33; 95% CI 0.81-2.20) or with clopidogrel (HR 1.09; 95% CI 0.76-1.56) (interaction; P = .53). Conclusions: We observed no interaction between vorapaxar and clopidogrel after non-ST-segment elevation acute coronary syndromes on efficacy or safety outcomes, supporting a complementary role of protease-activated receptor 1 and P2Y12 antagonism.

    Original languageEnglish
    Pages (from-to)869.e1-877.e1
    Number of pages9
    JournalAmerican Heart Journal
    Volume168
    Issue number6
    DOIs
    Publication statusPublished - 2014

    Fingerprint Dive into the research topics of 'Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial'. Together they form a unique fingerprint.

  • Cite this

    Tricoci, P., Lokhnygina, Y., Huang, Z., Van De Werf, F., Cornel, J., Chen, E., Wallentin, L., Held, C., Aylward, P., Moliterno, D., Jennings, L., White, H., Armstrong, P., Harrington, R., Strony, J., & Mahaffey, K. (2014). Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. American Heart Journal, 168(6), 869.e1-877.e1. https://doi.org/10.1016/j.ahj.2014.09.002